Suraksha Diagnostics, one of Eastern India’s leading diagnostic chains, has unveiled its state-of-the-art Genomics Lab in Kolkata, marking a transformative step in the region’s healthcare journey. Inaugurated on July 4, 2025, the grand event was graced by Professor Sukumar Mukherjee, a renowned rheumatologist and mentor at Suraksha Diagnostics.
With an initial investment of ₹22 crore and an additional ₹46 crore planned over the next 24 months, the lab is one of the largest and most advanced in Eastern India. It aligns with a broader vision to make precision diagnostics accessible and integrated into everyday clinical care. The genomics lab is equipped with cutting-edge technologies including Cytogenetics, Chromosomal Microarray, Sanger Sequencing, and Next-Generation Sequencing (NGS), enabling a wide spectrum of advanced genetic testing.
West Bengal, long known as a cradle of education and culture, is witnessing a resurgence in medical innovation. Suraksha Diagnostics recognized the growing need for accessible genomic services and responded with a lab designed to support predictive, preventive, and personalized care. This facility empowers early detection of chromosomal conditions such as Down syndrome, Edwards syndrome, and Patau syndrome, while offering expert genetic counseling for informed decision-making.
In the field of oncology, Suraksha is pioneering onco-genomics in the region, with advanced hereditary cancer testing for breast, ovarian, and colorectal cancers. The lab offers both germline and somatic mutation profiling, supporting personalized cancer risk assessments and treatment strategies. With NGS-powered oncology panels, clinicians can now identify actionable mutations that guide precision therapies—making Suraksha one of the few centers in Eastern India offering truly personalized cancer diagnostics.
The lab’s genetic testing capabilities begin with karyotyping, visualizing all 46 chromosomes to detect major abnormalities. For deeper insights, Chromosomal Microarray uncovers subtle genetic changes, while FISH technology targets specific concerns. Sanger Sequencing offers gene-level precision, and NGS provides an expansive view of millions of genetic markers linked to complex conditions.
Dr. Somnath Chatterjee, Chairman and Joint Managing Director of Suraksha Diagnostics, noted that genomics is at the heart of a global medical revolution. “By unlocking the secrets of the human genome, we can diagnose earlier, predict more accurately, and treat more precisely—from fetal medicine to rare diseases and cancer,” he said.
Ritu Mittal, CEO and Managing Director, emphasized the lab’s mission to provide comprehensive, end-to-end genetic testing across prenatal, pediatric, reproductive, and oncological domains. She reaffirmed Suraksha’s commitment to quality and accessibility, ensuring that clinicians and families in Eastern India no longer need to send samples outside the region.
With the global genetic testing market expected to grow from USD 38.77 billion in 2024 to over USD 186 billion by 2035, Suraksha Diagnostics is positioning itself at the forefront of India’s precision healthcare movement. The company also plans to contribute to national goals in rare disease detection, newborn screening, and preventive genomics, while expanding its presence in research and public health initiatives.
Established in 1992, Suraksha Diagnostics has grown into a trusted name in healthcare, offering over 2,300 diagnostic tests across pathology, radiology, and medical consultancy. With a network that includes a central reference lab, eight satellite labs, 59 diagnostic centers, and 166 collection centers across West Bengal, Bihar, Assam, and Meghalaya, Suraksha continues to innovate through AI-enabled smart labs and digital platforms. Its ₹846.25 crore IPO in December 2024, subscribed 1.27 times, reflects the strong confidence of investors in its growth trajectory
